Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1/2 study titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma. The study aims to assess the safety and efficacy of ABBV-453, a BCL-2 inhibitor, in adult participants with relapsed/refractory multiple myeloma (MM). This research is significant as it explores new treatment options for MM, a challenging plasma cell disease.
The study tests ABBV-453, an investigational oral drug, alone or in combination with other antimyeloma agents like daratumumab, dexamethasone, and pomalidomide. The goal is to find the optimal dosage and assess the drug’s impact on disease activity.
This interventional study is randomized with a sequential intervention model and no masking. Its primary purpose is treatment, focusing on determining the safety and effectiveness of ABBV-453 in different combinations.
The study began on July 23, 2025, with an estimated completion timeline of 4.5 years. The primary completion date is yet to be determined, and the latest update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The study’s outcome could significantly impact AbbVie’s stock performance by potentially introducing a new treatment for MM, influencing investor sentiment positively. Given the competitive landscape of MM treatments, successful results could position AbbVie favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.